Celebrating Progress: 50 Years of Life Science Breakthroughs Transforming Medicine and Global Health

2026 marks an extraordinary milestone in the history of science and medicine: the 50th anniversary of modern biotechnology, tracing back to the foundational emergence of recombinant DNA and genetic engineering in the 1970s. Over the past five decades, biotech has matured from the potential promise of treatments and cures once thought unimaginable, to a robust engine of medical progress that has reshaped patient care and public health.

Biotechnology’s roots in modern medicine began with early achievements such as the development of recombinant DNA, which enabled scientists to cut and recombine DNA sequences and paved the way for biologic medicines and genetic therapies. This era also saw the first monoclonal antibody and recombinant human insulin—treatments that transformed chronic disease management and set the stage for personalized medicine.

2026 also marks the 20th anniversary of the California Biotechnology Foundation’s (CBF) commitment to supporting life-changing innovations. Even since CBF’s inception two decades ago, we’ve witnessed remarkable breakthroughs: the commercialization of CRISPR gene-editing tools that allow precise DNA changes; the advent of CAR-T cell therapies that revolutionized cancer treatment; and next-generation vaccines that ended a global pandemic and accelerated vaccine science far beyond what was once conceivable. These milestones, driven in part by California’s vibrant life science ecosystem, underscore California’s worldwide leadership in innovation.

Even in the past year alone, the life science industry delivered a notable lineup of advances that have immediate impact on patients’ lives and the future of healthcare. Among them:

• The first twice-yearly injectable for HIV prevention, lenacapavir, provides highly effective, long-acting protection with only two shots per year.
• The approval of needle-free epinephrine spray for emergency allergy treatment that broadens access and ease of use for those with severe allergies.
• Novel genetic and immune-based therapieswere also introduced, including the first gene editing treatment administered to a baby with a rare metabolic disorder that helped avert a life-threatening liver transplant.
• Renewed momentum in precision medicine and gene editing approaches that are laying the groundwork for future cures in rare diseases.
• Suzetrigine was approved as the first novel non-opioid analgesic targeting pain pathways without addiction risk, reflecting the role of the life science industry in addressing the national opioid crisis.
• Continued progress in Alzheimer’s disease, as disease-modifying therapies targeting amyloid biology demonstrated meaningful slowing of cognitive decline in early-stage patients, reinforcing the importance of early detection and long-term investment in neurodegenerative research.
• Galleri® multi-cancer early detection test, which can identify signals associated with more than 50 cancers from a single blood draw and, when paired with routine screening, has been shown to increase overall cancer detection more than seven-fold—offering the potential to identify cancer earlier, often before symptoms appear.

As we look toward 2026, the momentum continues. The FDA is expected to decide on multiple cutting-edge biologics, including gene therapies and next-generation antibody treatments for autoimmune and rare diseases, as well as innovative vaccines aimed at Lyme disease and cytomegalovirus. In addition, growing evidence around GLP-1 therapies is expected to further demonstrate benefits beyond obesity and diabetes—including potential impacts on cardiovascular disease and Alzheimer’s—alongside advances such as an oral GLP-1 pill and ongoing research into long-acting, one-time injection formulations that could transform chronic disease prevention and treatment. Meanwhile, the strategic biotech pipeline includes potential approvals for therapies addressing narcolepsy, targeted gastric cancers, and next-generation respiratory vaccines, signaling continued broad impact across diverse patient populations.

Beyond individual therapies, the broader life science ecosystem is advancing AI-enabled drug discovery, in-vivo gene editing, and next-generation precision medicine platforms, accelerating development timelines and expanding what is possible in patient care.

As we celebrate these dual anniversaries, CBF reaffirms its mission: to support innovation and inform legislative policies that translate scientific discovery into real therapies that improve and save lives. California’s sustained leadership in life sciences not only fuels economic growth—it delivers hope, earlier diagnoses, and better outcomes for patients across our state and around the world.